Biocom California Applauds Government Funding and FDA User Fees Reauthorization Measure

SOUTH SAN FRANCISCO & LOS ANGELES & SAN DIEGO & WASHINGTON–(BUSINESS WIRE)–Biocom California, the association representing the life science industry of California, issued the following statement regarding passage of the Fiscal Year (FY) 2023 Continuing Resolution in the Senate and House of Representatives this week. The statement can be attributed to Joe Panetta, Biocom California’s president and CEO: “Biocom California applauds the Senate and House of Representatives for passing legislation
Click here to view original post